Form 4: Dyne Therapeutics SVP Richard Scalzo Reports Stock Option Exercises and Share Sales
SEC Form 4
Richard Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, exercised stock options and sold shares on September 6, 2024.
Summary
- Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, filed a Form 4 on September 10, 2024.
- On September 6, 2024, Scalzo exercised multiple stock options at various prices ($5.54, $19, $13.12, $8.58, $10.72, and $10.88) and acquired a total of 116,878 shares.
- He also sold 126,074 shares of common stock at a weighted average price of $32.14 and $32.63.
- Following these transactions, Scalzo directly owns 101,426 shares of Dyne Therapeutics, including 101,426 unvested RSUs.
- He also holds options to purchase 114,942 shares.
Sentiment
Score: 5
Explanation: This is a neutral document reflecting routine insider transactions. The sentiment is neither particularly positive nor negative.
Industry Context
Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Comparing Scalzo's transactions to similar insider sales at comparable biotech companies would require analyzing Form 4 filings of executives at companies like Sarepta Therapeutics or BioMarin Pharmaceutical.
- Typical vesting schedules for stock options in the biotech industry are four years, with monthly or quarterly installments, which aligns with the vesting schedules described in the document.
- The sale price of approximately $32.14 and $32.63 would need to be compared to the prevailing market price of DYN stock at the time to assess whether the sales were opportunistic or part of a pre-planned strategy.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they reflect insider selling activity.
- The impact on employees, customers, suppliers, and creditors is likely to be negligible.
Key Dates
| Date | Description |
|---|---|
| 07/31/2020 | Date of grant for some stock options with vesting over four years. |
| 09/16/2020 | Date of grant for some stock options with vesting over four years. |
| 12/10/2021 | Date of grant for some stock options with vesting over four years. |
| 07/11/2022 | Date of grant for some stock options with vesting over four years. |
| 12/09/2022 | Date of grant for some stock options with vesting over four years. |
| 11/15/2023 | Date of grant for some stock options with vesting over four years. |
| 09/06/2024 | Date of stock option exercises and share sales. |
| 09/10/2024 | Date of Form 4 filing. |
| 07/30/2030 | Expiration date for some stock options. |
| 09/15/2030 | Expiration date for some stock options. |
| 12/09/2031 | Expiration date for some stock options. |
| 07/10/2032 | Expiration date for some stock options. |
| 12/08/2032 | Expiration date for some stock options. |
| 11/14/2033 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.